GERN - Geron Corporation

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
5.46
-0.04 (-0.73%)
At close: 4:00PM EDT

5.49 +0.03 (0.55%)
After hours: 7:56PM EDT

Stock chart is not supported by your current browser
Previous Close5.50
Open5.50
Bid5.47 x 2900
Ask5.49 x 1800
Day's Range5.44 - 5.58
52 Week Range1.74 - 6.99
Volume6,841,437
Avg. Volume5,793,000
Market Cap1.003B
Beta2.68
PE Ratio (TTM)N/A
EPS (TTM)-0.18
Earnings DateMay 4, 2017 - May 8, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.75
Trade prices are not sourced from all markets
  • 7 Biotech Stocks to Buy Now
    InvestorPlace2 days ago

    7 Biotech Stocks to Buy Now

    Now that the biotechnology sector is well on its way to bouncing back after bottoming in May 2018, investors may feel like they missed out. The fears that previously plagued biotech stocks are no longer as big a threat. The government is no longer putting companies hiking drug price in their cross-hairs, at least not for now. This favorable environment should help biotech firms carry out their plans for the rest of the year.

  • ACCESSWIRE2 days ago

    Stem Cell Deals Moving the Markets

    HENDERSON, NV / ACCESSWIRE / September 19, 2018 / The stem cell market has been very active recently, several stocks have been making deals and major breakthroughs. One stem cell play the market seems ...

  • ACCESSWIRE5 days ago

    Today's Research Reports on Trending Tickers: Geron and Arrowhead Pharmaceuticals

    On Thursday, President Donald Trump instructed aides to carry on with $200 billion tariffs against Chinese goods. The Nasdaq Composite Index dropped 0.05 percent to close at 8,010.04, gained 1.4 percent for the week.

  • Benzinga5 days ago

    The Week Ahead In Biotech (Sept. 16-22): Conferences, PDUFA Dates, Clinical Trial Results And IPOs

    Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...

  • ACCESSWIRE7 days ago

    Major Stem Cell Breakthroughs Giving Investors Big Opportunity

    HENDERSON, NV / ACCESSWIRE / September 14, 2018 / Last week, Sangamo Therapeutics became the first company to edit a patient's DNA inside the body, usually the process is done outside the body. This is ...

  • Options Traders Expect Huge Moves in Geron (GERN) Stock
    Zacks8 days ago

    Options Traders Expect Huge Moves in Geron (GERN) Stock

    Geron (GERN) needs investors to pay close attention to the stock based on moves in the options market lately.

  • Motley Fool9 days ago

    Geron Corp: Lost in Translation?

    Geron's full value may take some time to materialize, but that's not necessarily a bad thing.

  • Geron: One of the Best-Performing Biotech Stocks in Past Month
    Market Realist9 days ago

    Geron: One of the Best-Performing Biotech Stocks in Past Month

    Geron (GERN) has been one of the best-performing biotechnology companies in the last month, rising 67.1% since August 10. On November 13, 2014, Geron announced a collaboration with Janssen Biotech, a subsidiary of Johnson & Johnson, for the development and commercialization of imetelstat, its investigational telomerase inhibitor across various hematologic malignancies and especially in myelofibrosis (or MF).

  • Motley Fool10 days ago

    Geron Corporation: A Sober Assessment

    Geron may be reaching a top. Here's why.

  • ACCESSWIRE14 days ago

    3 Stocks to Watch as Immunotherapy Pushes Biotech Growth

    The big focus as of late has been on immunotherapies and advanced regenerative therapies, which has helped drive innovation and new growth within the space. Specifically, cancer immunotherapy is expecting strong growth based on the increased number of deaths as a result of cancer. New treatments beyond basic chemotherapy are being developed and higher demand for things like immunotherapy continue to push the need for companies to adapt.

  • ACCESSWIRE15 days ago

    5 Biotech Stocks to Watch

    HENDERSON, NV / ACCESSWIRE / September 6, 2018 / Biotech stocks have been making investors major profits for years. Recently, the stem cell market has started to heat up again. One stock leading that push ...

  • 3 Biotech Stocks That Still Have Major Catalysts in September
    Motley Fool16 days ago

    3 Biotech Stocks That Still Have Major Catalysts in September

    Clinical trial results on the way could change the way investors feel about these biotech stocks before the leaves start falling.

  • 3 Top Stocks Under $10
    Motley Fool17 days ago

    3 Top Stocks Under $10

    These low-priced stocks could generate high returns.

  • Geron Stock Up More Than 200% in 2018 So Far: Here's Why
    Zacks17 days ago

    Geron Stock Up More Than 200% in 2018 So Far: Here's Why

    Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in Janssen sponsored studies.

  • Why Geron Corp. Soared 59.6% in August
    Motley Fool19 days ago

    Why Geron Corp. Soared 59.6% in August

    Evidence suggests a key decision will go its way soon.

  • Benzinga19 days ago

    The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials And Earnings

    The biotech sector notched strong gains last week, capitalizing on the positive overall market sentiment, set in motion by the trade deal between the U.S. and Mexico. Here are a few catalysts that could ...

  • 3 Biotech Stocks That Could Soar Next Week
    Motley Fool19 days ago

    3 Biotech Stocks That Could Soar Next Week

    Amarin Corporation, CRISPR Therapeutics, and Geron Corporation could all see big gains next week. Here's why.

  • Why Is Geron (GERN) Up 58% Since Last Earnings Report?
    Zacks22 days ago

    Why Is Geron (GERN) Up 58% Since Last Earnings Report?

    Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • ACCESSWIRE23 days ago

    Biotech and Cannabis Stocks Preparing to Breakout

    HENDERSON, NV / ACCESSWIRE / August 30, 2018 / Small-Cap Biotech and Cannabis stocks have been receiving a lot of attention from the investment community as of late. With conference season right around ...

  • Why Yum China Holdings, Brooks Automation, and Geron Jumped Today
    Motley Fool24 days ago

    Why Yum China Holdings, Brooks Automation, and Geron Jumped Today

    Find out how potential M&A activity lifted some of these stocks.

  • Why Geron Corporation's Stock Is Charging Higher Today
    Motley Fool24 days ago

    Why Geron Corporation's Stock Is Charging Higher Today

    The cancer drug company is showing no signs of slowing down after its breakout last Friday.

  • Johnson & Johnson Is Hiring -- and It's Ginormous News for Geron
    Motley Fool24 days ago

    Johnson & Johnson Is Hiring -- and It's Ginormous News for Geron

    A new job posted by the healthcare giant hints that good news could be on the way for Geron.

  • Geron Stock Rose 32% in Week Ended August 24
    Market Realist25 days ago

    Geron Stock Rose 32% in Week Ended August 24

    On August 24, Geron (GERN) stock rose ~28.78% to $5.19 from its prior day’s close of $4.03. On August 24, Geron stock was ~29% below its 52-week high of $6.68 on March 22. On August 24, Johnson & Johnson (JNJ) posted a job opening that mentioned imetelstat.

  • Has Geron Corporation's Stock Been De-Risked?
    Motley Fool25 days ago

    Has Geron Corporation's Stock Been De-Risked?

    Last Friday, Geron's shares spiked on a job posting by its partner Johnson & Johnson that seems to indicate that a key decision on a drug is near.

  • ACCESSWIRE28 days ago

    3 Biotech Stocks Hitting New Highs in August 2018

    CORAL GABLES, FL / ACCESSWIRE / August 24, 2018 / The Medical sector is one of the sectors to have recorded consistent earnings growth over the last few quarters. GT Biopharma (GTBP) saw its shares climb to highs of $2.10 on Friday morning. The company announced today that it has appointed David Cardino, CPA, MBA as Vice President of Finance.